Login to Your Account

UK Could Save $136.9M Annually

Genentech's Avastin, Lucentis Are Equally Good in Wet AMD

By Nuala Moran
Staff Writer

Tuesday, May 8, 2012
LONDON – A head-to-head study funded by the UK Department of Health has found Avastin and Lucentis are equally effective and safe in treating wet age-related macular degeneration (AMD), and that using Avastin off-label in this indication would save the National Health Service £84.5 million (US$136.9 million) per year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription